Neurofibromatosis type 2 (NF2): a clinical and molecular review - Wikidata - wikimedia - TriplyDB

Neurofibromatosis type 2 (NF2): a clinical and molecular review

Neurofibromatosis type 2 (NF2): a clinical and molecular review

http://www.wikidata.org/entity/Q21202892

about

A Comprehensive Review of Pediatric Tumors and Associated Cancer Predisposition Syndromes.First insight into the somatic mutation burden of neurofibromatosis type 2-associated grade I and grade II meningiomas: a case report comprehensive genomic study of two cranial meningiomas with vastly different clinical presentation.Abdominal schwannoma in a case of neurofibromatosis type 2: A report of a rare combination.Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas Childhood neurofibromatosis type 2 (NF2) and related disorders: from bench to bedside and biologically targeted therapies.Tumor suppressor Nf2/merlin drives Schwann cell changes following electromagnetic field exposure through Hippo-dependent mechanisms.Mutations in LZTR1 add to the complex heterogeneity of schwannomatosis Neurofibromatosis type 2 patient presenting with medulloblastoma.Multiple synchronous sites of origin of vestibular schwannomas in neurofibromatosis Type 2.Neurofibromatosis type 2: Intracranial calcifications as a clue to diagnosis miRNA-7 attenuation in Schwannoma tumors stimulates growth by upregulating three oncogenic signaling pathways Gastrinoma and neurofibromatosis type 2: the first case report and review of the literature.NF2/merlin in hereditary neurofibromatosis 2 versus cancer: biologic mechanisms and clinical associations.Radiographic association of schwannomas with sensory ganglia.Auditory rehabilitation of patients with neurofibromatosis Type 2 by using cochlear implants.Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside.Treatment of vestibular schwannoma cells with ErbB inhibitors Preclinical validation of AR42, a novel histone deacetylase inhibitor, as treatment for vestibular schwannomas.AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas.Temporal bone histopathology in neurofibromatosis type 2.Microdeletion del(22)(q12.2) encompassing the facial development-associated gene, MN1 (meningioma 1) in a child with Pierre-Robin sequence (including cleft palate) and neurofibromatosis 2 (NF2): a case report and review of the literature.The molecular biology of vestibular schwannomas and its association with hearing loss: a review.Multiple primary cranio-spinal tumours in a 13-year-old female with neurofibromatosis type 2 management strategy.A Rare Case of Radiologically Not Distinguishable Coexistent Meningioma and Vestibular Schwannoma in the Cerebellopontine Angle - Case Report and Literature Review.Angiosarcoma arising in schwannoma of cerebellopontine angle and later associating with meningioma in a patient with neurofibromatosis type 2.Longitudinal evaluation of quality of life in 288 patients with neurofibromatosis 2.A rare retroperitoneal schwannoma in a patient with neurofibromatosis Type 2.Characterization and utilization of an international neurofibromatosis web-based, patient-entered registry: An observational study.Differential NF2 Gene Status in Sporadic Vestibular Schwannomas and its Prognostic Impact on Tumour Growth Patterns A patient with mosaic neurofibromatosis type 2 presenting with early onset meningioma Achieving consensus for clinical trials: the REiNS International Collaboration.Inhibition of SIRT2 in merlin/NF2-mutant Schwann cells triggers necrosis.A chemical biology approach identified PI3K as a potential therapeutic target for neurofibromatosis type 2 Recent developments in brain tumor predisposing syndromes.Role of Merlin/NF2 inactivation in tumor biology.Getting personal: Head and neck cancer management in the era of genomic medicine.Lisch and the Importance of His Nodules.The Conundrum of Genetic "Drivers" in Benign Conditions.The molecular pathogenesis of schwannomatosis, a paradigm for the co-involvement of multiple tumour suppressor genes in tumorigenesis.Malignancy in vestibular schwannoma after stereotactic radiotherapy: a case report and review of the literature.

P2860

Q30252766-7BC8E83F-2D12-4702-8C2B-1223AEF8EDCC Q30274790-02C040CF-8471-41A2-BB1D-231BD6BB6EB0 Q30358638-1C6DDA3D-12AF-4561-B352-B5F794E43045 Q30359059-579ACF71-8EF8-4758-8D0D-51160AA78643 Q30364937-8D127CB4-BC2C-4A99-82D6-9538534D2B86 Q30376040-C7D9817B-FD7D-4B7A-B005-25F4AC999C8A Q30394068-FAA2265F-AFB6-4566-8244-B12F83C35DFF Q30399531-5CEB7421-CB69-4FD2-9467-3C2809C76D91 Q30405514-7960836C-82A3-4850-B074-DB04949B8C28 Q30421923-2B42EAD8-D88A-4653-A5F3-64C7435AC1C3 Q30428483-9E1A0A4B-7357-4DBC-9FB3-23E43D1A4A05 Q30435359-36DEED37-FC86-46C4-AFBB-287EA4738A97 Q30440530-A16D392E-8C02-4AD6-86C6-51F2A006FC86 Q30450062-077C1406-AA7F-47A1-BF3A-5495132720EB Q30457595-F6855244-B463-4A94-A843-68BD12BFE43D Q30458310-E1ED3DAC-24A6-4C44-AC45-0430FF7CA239 Q30458767-44858225-BE0B-4AD6-A9DB-D96242DE078D Q30459589-F635E2F1-AFF4-44EC-93A0-56FA7C5C65BF Q30464276-7EF686C3-D04D-4CF1-8F34-8C68B347D5FF Q30466218-168F4CA5-D540-4DD2-BADB-59AF4E9555FC Q30467373-16BFA3C1-6E96-4C0C-96A1-DB924AFE5B76 Q30467803-DBACDCE0-313F-40DD-BC93-2F01D28EDFEB Q30477143-1E4D6CE8-013B-421F-AF73-496D1C92CFD3 Q30478827-38AB8497-0ECA-4D9D-8857-D6422D86144A Q30771588-D586269F-8D7A-40E3-A5B8-13A63893BCF9 Q33561323-8864A53F-E5EE-46B0-94BB-BDEE03012E52 Q33816942-A8208307-C438-44DE-855A-631D7027B25C Q33828856-C2B8BB9E-08CB-4B3E-9C77-E69E5F5A8AE6 Q33906075-222B2ADA-7D48-4D9A-BE82-FF77FFE6C2D3 Q34573639-B971CA1D-2FB8-4F20-9441-036A404CE13D Q35046436-34BE7FF8-6854-4A88-B482-73CA10E40A50 Q35047921-53D45419-02E1-4F85-A20E-77D7B1DC7184 Q35380714-2733FA62-8DF5-42A8-90A5-BF3D7D6FC11D Q35860402-F63B2C64-DDD8-49C3-AC96-6162C6FE9D7C Q36189820-039DBB56-1C32-4376-8855-553D810F32AF Q36303715-190BCAB0-9815-42E1-9E99-4016E13621A9 Q36345004-A829545A-39B8-41B4-9FF1-452CA5AAB82F Q37245787-B83B03E6-A59B-4135-A656-234437B4802C Q37601480-FC161D0B-CC44-464B-98BB-8785544EB502 Q37869022-AEA505A2-4DC9-45CC-9464-700939C1974E

P2860

Neurofibromatosis type 2 (NF2): a clinical and molecular review

http://www.wikidata.org/entity/Q21202892

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

name

Neurofibromatosis type 2 (NF2): a clinical and molecular review

@ast

Neurofibromatosis type 2 (NF2): a clinical and molecular review

@en

Neurofibromatosis type 2 (NF2): a clinical and molecular review

@en-gb

Neurofibromatosis type 2 (NF2): a clinical and molecular review

@nl

type

label

Neurofibromatosis type 2 (NF2): a clinical and molecular review

@ast

Neurofibromatosis type 2 (NF2): a clinical and molecular review

@en

Neurofibromatosis type 2 (NF2): a clinical and molecular review

@en-gb

Neurofibromatosis type 2 (NF2): a clinical and molecular review

@nl

altLabel

Neurofibromatosis type 2 (NF2): A clinical and molecular review

@en

prefLabel

Neurofibromatosis type 2 (NF2): a clinical and molecular review

@ast

Neurofibromatosis type 2 (NF2): a clinical and molecular review

@en

Neurofibromatosis type 2 (NF2): a clinical and molecular review

@en-gb

Neurofibromatosis type 2 (NF2): a clinical and molecular review

@nl

P1433

Q21202892-3F16515F-A20B-4A52-B6A4-13966A84AAD1

P1476

Q21202892-3107C85F-E80A-4562-AD3E-0D5F16CE0444

P275

Q21202892-3D84968A-7CFA-4D2E-B7D8-71DFC25403C6

P2860

Q21202892-016C5164-F9F1-441D-B79E-20C1AB028264

Q21202892-0C7C9506-9203-479C-8A7E-F8733008B115

Q21202892-0D2C13DD-3403-45A0-B440-5E0B5B84BF25

Q21202892-0DBCC22B-4632-4A93-90F7-ECAD04C6CBE5

Q21202892-106E732F-177C-4EEB-A628-FF31C436F389

Q21202892-17E5F870-C822-4ED8-ADE8-0313E82FF270

Q21202892-1D277A06-F338-40B2-B2E4-48C484F35CC1

Q21202892-1D4440DB-6673-48CD-80FE-D2B5F9107A90

Q21202892-2926D912-D2F0-4701-8127-17AB917B8A0C

Q21202892-2CE58DE1-00DF-4A21-B706-4665FDAB36D5

P2888

Q21202892-5BB15D75-E008-485F-BB44-7DF5AB08F440

P304

Q21202892-F7E20922-A82D-4FFC-89A9-425C6114A417

P31

Q21202892-6481E5B2-2733-4056-B2AA-7D4C6F897212

Q21202892-7309CBD2-ED36-49F0-92FC-75402B834F3B

P3181

Q21202892-BE9781C8-D355-4E76-B89A-23326D17FAAD

P356

Q21202892-A592490F-0F16-4F0F-B354-CBC20BBD39EE

P407

Q21202892-70D77819-EECD-4C97-BE48-0A29BDE699BD

P433

Q21202892-B800AAF8-56E7-4F72-A98F-F1CBE2AA459D

P478

Q21202892-2DAA51F2-2D98-457F-A572-D7E75F71403C

P50

Q21202892-577BBD08-DF71-4A90-B03F-D5B60155F733

P5008

Q21202892-CFE69131-D8AC-4D62-AE69-7DD48C809B6F

P577

Q21202892-C4E9CF21-E936-45DE-9B9F-08D2CF0F93FE

P5875

Q21202892-1F865B72-C7E5-4020-8C5E-B6080A17F2CB

P6179

Q21202892-E83DB067-E4D2-4738-A3D3-DB3B5F67E648

P698

Q21202892-2BDD065F-055B-442C-9AB2-B8284C7AAA0F

P921

Q21202892-508E4F84-EF33-49CE-A704-ABD1E19D2C81

P932

Q21202892-BA103910-714B-41C4-812B-EF6FF6471514

P3181

P356

P1433

Orphanet Journal of Rare Diseases

P1476

Neurofibromatosis type 2 (NF2): a clinical and molecular review

@en

P275

Creative Commons Attribution 2.0 Generic

P2860

Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2

Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2.

Mosaicism in neurofibromatosis type 2: an update of risk based on uni/bilaterality of vestibular schwannoma at presentation and sensitive mutation analysis including multiple ligation-dependent probe amplification.

Age related shift in the mutation spectra of germline and somatic NF2 mutations: hypothetical role of DNA repair mechanisms.

Paediatric presentation of type 2 neurofibromatosis.

Identification of recurrent regions of chromosome loss and gain in vestibular schwannomas using comparative genomic hybridisation.

Molecular study of frequency of mosaicism in neurofibromatosis 2 patients with bilateral vestibular schwannomas.

Molecular genetic analysis of the NF2 gene in young patients with unilateral vestibular schwannomas.

Genotype/phenotype correlations in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations

A genetic study of type 2 neurofibromatosis in the United Kingdom. II. Guidelines for genetic counselling

P2888

P304

16

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2427700

http://www.w3.org/2001/XMLSchema#string

P356

10.1186/1750-1172-4-16

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

P5008

P577

2009-06-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26309969

http://www.w3.org/2001/XMLSchema#string

P6179

1017134341

http://www.w3.org/2001/XMLSchema#string

P698

19545378

http://www.w3.org/2001/XMLSchema#string

P921

neurofibromatosis

P932

2708144

http://www.w3.org/2001/XMLSchema#string